Marco Toffoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marco Toffoli has a total of 316 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Henry Vernon Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
17 shared publications - Christos Proukakis
Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK
11 shared publications - Fritz Joachim Sedlazeck
Baylor College of Medicine
8 shared publications - Ziv Gan-Or
Department of Human Genetics, McGill University, Montreal, QC, Canada
7 shared publications - Karel Sonka
Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic
6 shared publications - Michela Figorilli
Department of Medical Sciences and Public Health, Sleep Disorder Research Center, University of Cagliari, Cagliari, Italy
6 shared publications
Latest Publications
- Open Access
Assessing the Accuracy of the NeuroBooster Array for GBA1 Variant Detection
GBA1 variants are major Parkinson’s disease risk factors, but their detection is challenging. We compared NeuroBooster Array (NBA) genotyping with reference sequencing in 3,744 individuals. NBA correctly identified 520/608 carriers (85.5%). Of 89 missed calls, 73 had no matching probe and 16 had missing calls. 25 participants had false positive calls. NBA should not be used alone for clinical decisions, but is very useful for large case control analysis.
Open AccessAssessing the Accuracy of the NeuroBooster Array for GBA1 Variant Detection
GBA1 variants are major Parkinson’s disease risk factors, but their detection is challenging. We compared NeuroBooster Array (NBA) genotyping with reference sequencing in 3,744 individuals. NBA correctly identified 520/608 carriers (85.5%). Of 89 missed calls, 73 had no matching probe and 16 had missing calls. 25 participants had false positive calls. NBA should not be used alone for clinical decisions, but is very useful for large case control analysis.
- Open Access
Bridging Genetics and Precision Medicine in Parkinson’s Disease through GP2
In the Global Parkinson’s Genetics Program (GP2) we aim to advance precision medicine by integrating large-scale clinico-genetic data from diverse populations worldwide. We investigated potentially trial-eligible carriers of pathogenic and high-risk GBA1 and LRRK2 variants and conducted a global precision-medicine survey across GP2 sites. Among 65,509 individuals with Parkinson’s disease, we identified 9,019 (13.8%) potentially trial-eligible genetic variant carriers, including 6,789 GBA1 , 2,084 LRRK2 , and 146 dual GBA1-LRRK2 carriers. Individuals were distributed across multiple global regions, many of which currently lack active gene-targeted trials, highlighting a global disparity between relevant variant carriers and the availability of disease modifying treatment trials. GP2’s unified framework supports equitable recruitment for gene-targeted therapeutic studies and helps address critical gaps in Parkinson’s disease genetics and future therapeutic development.
Open AccessBridging Genetics and Precision Medicine in Parkinson’s Disease through GP2
In the Global Parkinson’s Genetics Program (GP2) we aim to advance precision medicine by integrating large-scale clinico-genetic data from diverse populations worldwide. We investigated potentially trial-eligible carriers of pathogenic and high-risk GBA1 and LRRK2 variants and conducted a global precision-medicine survey across GP2 sites. Among 65,509 individuals with Parkinson’s disease, we identified 9,019 (13.8%) potentially trial-eligible genetic variant carriers, including 6,789 GBA1 , 2,084 LRRK2 , and 146 dual GBA1-LRRK2 carriers. Individuals were distributed across multiple global regions, many of which currently lack active gene-targeted trials, highlighting a global disparity between relevant variant carriers and the availability of disease modifying treatment trials. GP2’s unified framework supports equitable recruitment for gene-targeted therapeutic studies and helps address critical gaps in Parkinson’s disease genetics and future therapeutic development.
- 24 February 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (5) , 1081-1084
Ambroxol for Parkinson's Disease
- 24 February 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (5) , 1081-1084
Ambroxol for Parkinson's Disease
- Open Access
- 1 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11198
VACmap: an accurate long-read aligner for unraveling complex genomic rearrangements
Sequence alignment is essential for genomic research and clinical diagnostics, yet detecting complex rearrangements such as inversions, duplications, and gene conversions remains challenging due to allele complexity and limitations of current methods. We introduce VACmap, a non-linear mapping approach to enhance the detection and representation of all genetic variations. VACmap improves duplication detection from 20% to 90% in the Challenging Medically-Relevant Genes (CMRG) benchmark and improves characterization of complex inversions in repetitive regions and gene conversion events. It improves resolving clinically significant loci, including the LPA gene (with repetitive KIV-2 units linked to coronary heart disease), GBA1 and STRC genes (risk factors for Parkinson’s disease and hearing loss, respectively, affected by pseudogene recombination with GBAP1 and STRCP1). Here, we show that VACmap delivers better alignment accuracy and SV detection, providing a robust tool for genomic analysis and clinical insights, with potential to advance understanding of genetic diversity and disease mechanisms.
- 1 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 11198
Open AccessVACmap: an accurate long-read aligner for unraveling complex genomic rearrangements
Sequence alignment is essential for genomic research and clinical diagnostics, yet detecting complex rearrangements such as inversions, duplications, and gene conversions remains challenging due to allele complexity and limitations of current methods. We introduce VACmap, a non-linear mapping approach to enhance the detection and representation of all genetic variations. VACmap improves duplication detection from 20% to 90% in the Challenging Medically-Relevant Genes (CMRG) benchmark and improves characterization of complex inversions in repetitive regions and gene conversion events. It improves resolving clinically significant loci, including the LPA gene (with repetitive KIV-2 units linked to coronary heart disease), GBA1 and STRC genes (risk factors for Parkinson’s disease and hearing loss, respectively, affected by pseudogene recombination with GBAP1 and STRCP1). Here, we show that VACmap delivers better alignment accuracy and SV detection, providing a robust tool for genomic analysis and clinical insights, with potential to advance understanding of genetic diversity and disease mechanisms.
- Open Access
- 20 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1627
Single cell long read whole genome sequencing reveals somatic transposon activity in human brain
The advent of single cell DNA sequencing revealed astonishing dynamics of genomic variability, but failed at characterizing smaller to mid size variants that on the germline level have a profound impact. In this work we discover previously uncharacterized genomic dynamics in 18 cells from three human brains utilizing single cell long-read whole genome sequencing. This provides key insights into the dynamic of the genomes of individual cells and further highlights brain specific activity of transposable elements, but requires validation in larger studies.
- 20 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1627
Open AccessSingle cell long read whole genome sequencing reveals somatic transposon activity in human brain
The advent of single cell DNA sequencing revealed astonishing dynamics of genomic variability, but failed at characterizing smaller to mid size variants that on the germline level have a profound impact. In this work we discover previously uncharacterized genomic dynamics in 18 cells from three human brains utilizing single cell long-read whole genome sequencing. This provides key insights into the dynamic of the genomes of individual cells and further highlights brain specific activity of transposable elements, but requires validation in larger studies.
- Open Access
- 1 October 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-6
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials
Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.
- 1 October 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-6
Open AccessSevere GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials
Variants in the GBA1 gene are the commonest genetic risk factor for Parkinson disease (PD). Genotype-phenotype correlations exist but with conflicting data. Here, we compared the clinical phenotype of 183 idiopathic PD (iPD) patients, 39 severe GBA1-PD, 24 mild GBA1-PD, and 55 risk GBA1-PD. Compared to iPD, we observed that only severe GBA1-PD patients had a distinctive, more several clinical profile, characterised by worse depression, hyposmia, cognitive dysfunction, and possibly constipation.
- Open Access
- 9 May 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-4
Reply to: Is Gauchian genotyping of GBA1 variants reliable?
- 9 May 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-4
Open AccessReply to: Is Gauchian genotyping of GBA1 variants reliable?
- 29 April 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 135, 107854
Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker
- 29 April 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 135, 107854
Combined assessment of blood glucocerebrosidase activity and α-synuclein levels in GBA1 mutation carriers: A novel potential biomarker
- Open Access
Single cell long read whole genome sequencing reveals somatic transposon activity in human brain
The advent of single cell DNA sequencing revealed astonishing dynamics of genomic variability, but failed at characterizing smaller to mid size variants that on the germline level have a profound impact. In this work we discover novel dynamics in three brains utilizing single cell long-read sequencing. This provides key insights into the dynamic of the genomes of individual cells and further highlights brain specific activity of transposable elements.
Open AccessSingle cell long read whole genome sequencing reveals somatic transposon activity in human brain
The advent of single cell DNA sequencing revealed astonishing dynamics of genomic variability, but failed at characterizing smaller to mid size variants that on the germline level have a profound impact. In this work we discover novel dynamics in three brains utilizing single cell long-read sequencing. This provides key insights into the dynamic of the genomes of individual cells and further highlights brain specific activity of transposable elements.
- Open Access
- 11 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (12) , 2144-2154
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease
Glucocerebrosidase (GBA1) variants constitute numerically the most common known genetic risk factor for Parkinson's disease (PD) and are distributed worldwide. Access to GBA1 genotyping varies across the world and even regionally within countries. Guidelines for GBA1 variant counseling are evolving. We review the current knowledge of the link between GBA1 and PD, and discuss the practicalities of GBA1 testing. Lastly, we provide a consensus for an approach to counseling people with GBA1 variants, notably the communication of PD risk. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 11 September 2024
- Published by Wiley in Movement Disorders
- Vol. 39 (12) , 2144-2154
Open AccessConsensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease
Glucocerebrosidase (GBA1) variants constitute numerically the most common known genetic risk factor for Parkinson's disease (PD) and are distributed worldwide. Access to GBA1 genotyping varies across the world and even regionally within countries. Guidelines for GBA1 variant counseling are evolving. We review the current knowledge of the link between GBA1 and PD, and discuss the practicalities of GBA1 testing. Lastly, we provide a consensus for an approach to counseling people with GBA1 variants, notably the communication of PD risk. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.